Whole-body

(18)F-FDG-PET/MRI MPNST neurofibromatosis 1 sarcoma screening

Journal

The Journal of investigative dermatology
ISSN: 1523-1747
Titre abrégé: J Invest Dermatol
Pays: United States
ID NLM: 0426720

Informations de publication

Date de publication:
16 Feb 2024
Historique:
received: 13 06 2023
revised: 23 01 2024
accepted: 30 01 2024
medline: 19 2 2024
pubmed: 19 2 2024
entrez: 18 2 2024
Statut: aheadofprint

Résumé

Malignant peripheral nerve sheath tumors (MPNST) are the leading cause of death in Neurofibromatosis type 1 (NF1). They can result from premalignant neurofibromas (NF) including NF with atypia and atypical neurofibromatous neoplasms of uncertain biologic potential (ANNUBP). Some phenotypic characteristics have been described as associated with their development. The aim was to outline our use of whole-body

Identifiants

DOI: 10.1016/j.jid.2024.01.028 PMID: 38368929
pubmed: 38368929
pii: S0022-202X(24)00112-X
doi: 10.1016/j.jid.2024.01.028
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Laura Fertitta (L)

Department of Dermatology, National Referral Center for Neurofibromatoses, Henri Mondor Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), 94010 Créteil, France; INSERM U955, 94010, Créteil, France; INSERM, Centre d'Investigation Clinique 1430, National Referral Center for Neurofibromatoses, Henri-Mondor Hospital, Assistance Publique-Hôpitaux Paris (AP-HP), 94010 Créteil, France. Electronic address: https://twitter.com/LauraFertitta.

Arnaud Jannic (A)

Department of Dermatology, National Referral Center for Neurofibromatoses, Henri Mondor Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), 94010 Créteil, France; INSERM, Centre d'Investigation Clinique 1430, National Referral Center for Neurofibromatoses, Henri-Mondor Hospital, Assistance Publique-Hôpitaux Paris (AP-HP), 94010 Créteil, France.

Ouidad Zehou (O)

Department of Dermatology, National Referral Center for Neurofibromatoses, Henri Mondor Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), 94010 Créteil, France.

Christina Bergqvist (C)

Department of Dermatology, National Referral Center for Neurofibromatoses, Henri Mondor Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), 94010 Créteil, France.

Salah Ferkal (S)

Department of Dermatology, National Referral Center for Neurofibromatoses, Henri Mondor Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), 94010 Créteil, France; INSERM, Centre d'Investigation Clinique 1430, National Referral Center for Neurofibromatoses, Henri-Mondor Hospital, Assistance Publique-Hôpitaux Paris (AP-HP), 94010 Créteil, France.

Sabine Moryousef (S)

Department of Dermatology, National Referral Center for Neurofibromatoses, Henri Mondor Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), 94010 Créteil, France.

Lionel Lerman (L)

Department of Nuclear Medicine, Henri Mondor Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), 94010 Créteil, France.

Sébastien Mulé (S)

Department of Radiology, Henri Mondor Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), 94010 Créteil, France; Université Paris-Est Créteil (UPEC), 94010 Créteil, France.

Alain Luciani (A)

Department of Radiology, Henri Mondor Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), 94010 Créteil, France; Université Paris-Est Créteil (UPEC), 94010 Créteil, France.

Blanche Bapst (B)

Department of Neuro-radiology, Henri Mondor Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), 94010 Créteil, France.

Khaled Ezzedine (K)

Department of Dermatology, National Referral Center for Neurofibromatoses, Henri Mondor Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), 94010 Créteil, France; INSERM, Centre d'Investigation Clinique 1430, National Referral Center for Neurofibromatoses, Henri-Mondor Hospital, Assistance Publique-Hôpitaux Paris (AP-HP), 94010 Créteil, France; Université Paris-Est Créteil (UPEC), 94010 Créteil, France.

Nicolas Ortonne (N)

INSERM U955, 94010, Créteil, France; Université Paris-Est Créteil (UPEC), 94010 Créteil, France; Department of Pathology, National Referral Center for Neurofibromatoses, Henri Mondor Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), 94010 Créteil, France.

Emmanuel Itti (E)

Department of Nuclear Medicine, Henri Mondor Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), 94010 Créteil, France; Université Paris-Est Créteil (UPEC), 94010 Créteil, France.

Pierre Wolkenstein (P)

Department of Dermatology, National Referral Center for Neurofibromatoses, Henri Mondor Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), 94010 Créteil, France; INSERM U955, 94010, Créteil, France; INSERM, Centre d'Investigation Clinique 1430, National Referral Center for Neurofibromatoses, Henri-Mondor Hospital, Assistance Publique-Hôpitaux Paris (AP-HP), 94010 Créteil, France; Université Paris-Est Créteil (UPEC), 94010 Créteil, France. Electronic address: pierre.wolkenstein@aphp.fr.

Classifications MeSH